Clinical Trials Logo

Filter by:
NCT ID: NCT00366795 Terminated - Liver Cirrhosis Clinical Trials

Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver

SPARe-2
Start date: August 2006
Phase: Phase 3
Study type: Interventional

Primary: To evaluate the efficacy of satavaptan in the absence of concomitant diuretic drugs in reducing the recurrence of ascites. Secondary: To evaluate the tolerability and safety of satavaptan in the absence of concomitant diuretic drugs over a 52-week treatment period in patients with cirrhosis of the liver and recurrent ascites. The one-year double blind placebo controlled period is extended up to 2 years in a long term safety study (PASCCAL-2).

NCT ID: NCT00366379 Completed - Clinical trials for Diabetes Mellitus Type 2

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

Start date: July 2006
Phase: Phase 2
Study type: Interventional

This study will assess the efficacy, safety and tolerability of increasing doses of GK Activator (2) in patients with type 2 diabetes whose condition has not been optimally controlled with one previous oral antihyperglycemic agent. After a 2 week washout from their previous antidiabetic therapy, patients will receive GK Activator (2) orally, twice a day for 12 weeks, at increasing doses of 25mg bid to 200mg bid; doses will be titrated to achieve a target fasting glucose level (FPG) of <100mg/dL. The anticipated time on study treatment is <3 months, and the target sample size is 100-500 individuals.

NCT ID: NCT00366249 Completed - Diabetic Foot Clinical Trials

Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

Start date: January 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study was to look at the safety and effectiveness of a once-daily dose of tigecycline compared to ertapenem for the treatment of diabetic foot infections. The co-primary efficacy endpoints were not met.

NCT ID: NCT00365235 Completed - Coronary Disease Clinical Trials

Understanding the Genetic Basis of Familial Combined Hyperlipidemia in Mexican Individuals

Start date: July 2006
Phase: N/A
Study type: Observational

Familial combined hyperlipidemia (FCHL) is an inherited disorder characterized by elevated levels of cholesterol and triglycerides; it often occurs in Mexican individuals with coronary heart disease (CHD). The purpose of this study is to identify the specific genes that predispose Mexican individuals to FCHL.

NCT ID: NCT00364793 Completed - HIV Infections Clinical Trials

Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children

Start date: February 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of this study is to find the dose of Efavirenz for young children. The safety and how the medication is tolerated will also be studied.

NCT ID: NCT00364559 Completed - Stroke Clinical Trials

Effect of Rosuvastatin in Intracerebral Hemorrhage

Start date: August 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether rosuvastatin is effective in the management of acute phase of intracerebral hemorrhage and if it impact outcome by NIHSS.

NCT ID: NCT00364351 Completed - Clinical trials for Non Small Cell Lung Cancer

Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

Start date: August 2006
Phase: Phase 3
Study type: Interventional

To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib

NCT ID: NCT00362232 Completed - Clinical trials for Venous Thromboembolism

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

RECORD 4
Start date: June 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess if 10 mg BAY59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.

NCT ID: NCT00362115 Completed - Hypertension Clinical Trials

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

Start date: May 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, efficacy, and tolerability of azilsartan medoxomil, once daily (QD), in individuals with hypertension.

NCT ID: NCT00361894 Completed - Clinical trials for Venous Thromboembolism

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.

RECORD 3
Start date: February 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess if 10 mg Bay 59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.